Drug Approval | October 16, 2024
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Subscribe To Our Newsletter & Stay Updated
